?

News

2026-09-10

Material Information- (Supplemental Announcement of Material Information on August 6, 2026) Announcement of the newly appointed Chief Business Officer

1.Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel (CEO, COO, CMO, CSO, etc.), financial officer, accounting officer, corporate governance officer, chief information security officer, research and development officer, internal audit officer, or designated and non-designated representatives):Chief Business Officer 2.Date of occurrence of the

2026-09-07

Material Information- Announcement of the Board’s Resolution to Repurchase Treasury Shares

1.Date of the board of directors resolution:2026/09/07 2.Purpose of the share repurchase:To maintain the Company’s credit and shareholders’ equity. 3.Type of shares to be repurchased:Common shares 4.Ceiling on total monetary amount of share repurchase (NTD):3,496,279,112 5.Scheduled period for the repurchase:2026/09/08~2026/11/07 6.No.of shares to be repurchased (shares):3,000,000 7.Repurchase price range (NTD):80.00~126.00, should

2026-09-04

Material Information- Announces on behalf of the subsidiary Handa Oncology, LLC, regarding FDA’s denial of the Citizen Petition against 505(b)(2) new drug HND-039 Omcazio

1.Date of occurrence of the event:2026/09/04 2.Company name:Handa Oncology, LLC 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Subsidiaries 4.Reciprocal shareholding ratios:Not applicable 5.Cause of occurrence:Handa Oncology, LLC (hereinafter referred to as “Handa Oncology”), an indirectly held subsidiary of the Company, was informed on April 16, 2026 (U.S.

2026-09-04

Material Information- Announces on Behalf Handa Oncology, LLC, regarding the 505 (b)(2) new formulation drug HND-039 OMCAZIO receives U.S. FDA Final Approval (FA)

1.Date of occurrence of the event: 2026/09/04 2.Company name: Handa Oncology, LLC 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Subsidiaries 4.Reciprocal shareholding ratios: Handa Oncology, LLC is a 100% indirectly owned subsidiary of the Company. 5.Cause of occurrence: On September 03, 2026 (U.S. time) , Handa Oncology,

2026-08-28

Material Information- Regarding the 505(b)(2) new formulation drug HND-039 Omcazio patent infringement litigation has been voluntarily dismissed by the plaintiff

1.Parties to the legal matter: Plaintiff：Exelixis, Inc Defendant：Handa Pharmaceuticals, Inc., Handa Pharma, Inc. and Handa Oncology, LLC 2.Name of the court or punishing agency of the legal matter:United States District Court for DELAWARE 3.Reference/Case number of relevant documents of the legal matter: NO. 1:26-cv-00813-UNA 4.Date of occurrence of the event:2026/08/28 5.Details of

2026-08-27

Material Information- Announcement of the Completion of Registration for Capital Reduction through Cancellation of Treasury Shares

1.Date of the competent authority’s approval of capital reduction:2026/08/26 2.Date of completion of capitalization change registration:2026/08/26 3.Effect on the financial statements (including any discrepancy between the amount of paid-in capital and the no.of shares outstanding, and the effect on net worth per share): (1)Before the cancellation of treasury

2026-08-06

Material Information- Announcement of the newly appointed Chief Business Officer

1.Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel (CEO, COO, CMO, CSO, etc.), financial officer, accounting officer, corporate governance officer, chief information security officer, research and development officer, internal audit officer, or designated and non-designated representatives):Chief Business Officer 2.Date of occurrence of the change:2026/08/06 3.Name,